Faced with the current shortage of medicines, Bern wants to extend mandatory reserves of drugs and the obligation to declare stocks, says a top government official.
This content was published on
2 minutes
Keystone-SDA/jc
Italiano
it
Di fronte alla carenza di farmaci, la Svizzera prevede di incrementare le scorte di medicinali
Anti-epileptic drugs and medicines for Parkinson’s disease should be included in the mandatory reserves, Christoph Amstutz of the Federal Office for National Economic SupplyExternal link (FONES) told SRF radio on Friday. Medicines for mental disorders should also be included, said Amstutz, who heads the Therapeutic Products Division at FONES. If these drugs were to run out, it could have a very harmful effect on patients, he added.
For the first time, the authorities have classified the supply of certain drugs as “problematic”, Amstutz told SRF. In the past it has always been possible to resort to compulsory stockpiling or exchange of certain drugs in case of supply problems. Now, however, not all oral antibiotics are available, but that does not mean that people will die because of it.
Current shortages mostly concern medicines for children, according to Amstutz. This is mainly a seasonal phenomenon, due to the flu epidemic and infections in toddlers, but is also a side effect of the pandemic. He said more antibiotics have been used than in previous years.
The next stage would be if the situation were deemed “critical”, with individual products or whole groups of therapeutic agents no longer available. “I hope this will not happen in the future,” Amstutz said.
FONES is also working with the Federal Office of Public Health (FOPH) to develop a plan for security of medicine procurement. The intention is to make virtually all drugs reimbursed by health insurance funds subject to compulsory registration.
Swisscom receives greenlight for acquisition of Vodafone Italia
This content was published on
The takeover of Vodafone Italia by Swisscom is nearing completion. All relevant authorities have now approved the €8 billion (CHF7.45 billion) deal.
Novo Nordisk stock market plunge drags down Swiss device maker Ypsomed
This content was published on
The Danish pharmaceutical giant, Novo Nordisk, faced setbacks on Friday that weighed on the share price of Swiss injection device manufacturer Ypsomed.
Swiss press react to EU deal with mix of euphoria and scepticism
This content was published on
Swiss media reaction to the agreement between Switzerland and the EU varies widely. Some are celebrating, while others worry about what is to come.
Swiss Solidarity donations to tackle child abuse top CHF4 million
This content was published on
Swiss Solidarity, the humanitarian arm of the Swiss Broadcasting Corporation (SBC), has raised over CHF4 million ($4.3 million) to tackle child abuse.
EU Commission president says Swiss-EU deal is ‘historic’ agreement
This content was published on
At a joint media conference with Swiss President Viola Amherd in Bern, European Commission President Ursula von der Leyen spoke of a "day of joy".
Switzerland and EU reach deal on future bilateral relations
This content was published on
Switzerland and the European Union have announced a political agreement to update their trading relationship after almost a decade of difficult talks.
Addiction experts warn of shortage of methadone tablets
This content was published on
The Swiss Society of Addiction Medicine (SSAM) has warned of a possible shortage of methadone tablets in the coming weeks.
This content was published on
Switzerland is experiencing medicine shortages due to supply chain issues linked to Covid lockdowns in China and the Ukraine war.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.